Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy

Background Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransfe...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	International journal of clinical oncology Ročník 16; číslo 3; s. 257 - 263
Hlavní autoři:	Miura, Kazuhiro, Nakano, Hiroshi, Sakurai, Joe, Kobayashi, Shinjiro, Koizumi, Satoshi, Arai, Tatsuhiro, Shimamura, Tsukasa, Makizumi, Ryoji, Yamada, Kyoji, Miyajima, Nobuyoshi, Otsubo, Takehito, Koike, Junki
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Japan Springer Japan 01.06.2011 Springer Nature B.V
Témata:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aspartate aminotransferase to platelet ratio index Aspartate Aminotransferases - metabolism Bevacizumab Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Chemical and Drug Induced Liver Injury - diagnosis Chemical and Drug Induced Liver Injury - enzymology Chemical and Drug Induced Liver Injury - etiology Chemotherapy Chemotherapy-associated hepatotoxicity Chemotherapy-naive patients Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Leucovorin - administration & dosage Leucovorin - adverse effects Liver cancer Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Original Article Platelet Count Radiography Retrospective Studies Splenic volume index Splenomegaly Splenomegaly - blood Splenomegaly - chemically induced Splenomegaly - diagnostic imaging Splenomegaly - enzymology Surgical Oncology Toxicity Aspartate aminotransferase to platelet ratio index Splenomegaly Chemotherapy-naïve patients Splenic volume index Chemotherapy-associated hepatotoxicity
ISSN:	1341-9625, 1437-7772, 1437-7772
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Background Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated. Methods Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated. Results The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% ( p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX ( p < 0.05). Conclusion Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23
ISSN:	1341-9625 1437-7772 1437-7772
DOI:	10.1007/s10147-010-0176-0